Zura Bio Limited

Zura Bio Limited is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory disorders. Its pipeline includes Tibulizumab, a bispecific antibody that neutralizes both IL-17A and BAFF, currently in Phase 2 trials. The company also has Torudokimab (ZB-880), a monoclonal antibody targeting interleukin-33 that completed Phase 1 studies, and Crebankitug (ZB-168), a monoclonal antibody targeting interleukin-7 receptor alpha that also completed Phase 1 studies. These therapies aim to address conditions where the immune system attacks the body, such as rheumatoid arthritis or psoriasis.

Zura Bio Limited is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol ZURA. The trading currency is the US Dollar (USD), as the company is headquartered in the United States and its shares are traded on a US exchange. This listing provides investors with access to the company's stock within the US equity markets.

Zura Bio operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing novel drugs, particularly for autoimmune and inflammatory disorders. Biotechnology firms like Zura Bio typically use biological processes and living organisms to create therapies, distinguishing them from traditional pharmaceutical companies that often rely on chemical synthesis.

Zura Bio Limited is headquartered in Henderson, Nevada, United States. The company was founded in 2022, making it a relatively young clinical-stage biotechnology firm. Its operations are primarily based in the US, where it develops its pipeline of antibody-based therapies for autoimmune and inflammatory diseases. The company's location in Nevada places it within a growing biotech hub, though its research and development activities may extend beyond its headquarters.